A Phase 1 interventional study of tofacitinib (CP-690,550) modified-release formulation A and tofacitinib (CP-690,550) modified-release formulation B1 in Healthy, sponsored by Pfizer. Completed at 1 site in Singapore. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-01-12.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will explore the drug behavior and safety following a single dose of three different 22 milligram tofacitinib (CP-690,550) modified-release formulations in 30 healthy volunteers. These formulations will be compared to 10 milligram tofacitinib (CP-690-550) in an immediate-release formulation.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
tofacitinib (CP-690,550) modified-release formulation A-Fed
Drug: tofacitinib (CP-690,550) modified-release formulation A
tofacitinib (CP-690,550) modified-release formulation B1-Fed
Drug: tofacitinib (CP-690,550) modified-release formulation B1
tofacitinib (CP-690,550) modified-release formulation A-Fasted
Drug: tofacitinib (CP-690,550) modified-release formulation A
tofacitinib (CP-690,550) modified-release formulation B1-Fasted
Drug: tofacitinib (CP-690,550) modified-release formulation B1
tofacitinib (CP-690,550) modified-release formulation B2-Fasted
Drug: tofacitinib (CP-690,550) modified-release formulation B2
tofacitinib (CP-690,550) immediate-release formulation-Fasted
Drug: tofacitinib (CP-690,550) immediate-release formulation
A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered with food.
A single dose of 22 mg tofacitinib (CP-690,550) MR-B1 formulation administered with food
A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered without food
A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B1 administered without food
A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B2 administered without food
A single dose of 10 mg tofacitinib (CP-690,550) immediate-release formulation administered without food
AUCinf: Area under the plasma concentration-time profile from time 0 exprapolated to infinite time
Time frame: 72 hours post dose
AUClast: Area under the plasma concentration-time profile from time 0 to the last with quantifiable concentration
Time frame: 72 hours post dose
Cmax: Maximum plasma concentration of tofacitinib (CP-690,550)
Time frame: 72 hours post dose
Tmax: Amount of time tofacitinib (CP-690,550) is at maximum plasma concentration
Time frame: 72 hours post dose
t1/2: The time required for one half of the total amount of tofacitinib (CP-690,550) to be removed from the plasma
Time frame: 72 hours post dose
Frel: Relative bioavailability (Frel) of tofacitinib (CP-690,550) in the modified-release formulations compared to the immediate release formulation
Time frame: 24 hours post dose
The record gives a start of Nov 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib